» Articles » PMID: 32913635

Recent Advances in Understanding and Managing Secondary Hyperparathyroidism in Chronic Kidney Disease

Overview
Journal F1000Res
Date 2020 Sep 11
PMID 32913635
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Secondary hyperparathyroidism is a complex pathology that develops as chronic kidney disease progresses. The retention of phosphorus and the reductions in calcium and vitamin D levels stimulate the synthesis and secretion of parathyroid hormone as well as the proliferation rate of parathyroid cells. Parathyroid growth is initially diffuse but it becomes nodular as the disease progresses, making the gland less susceptible to be inhibited. Although the mechanisms underlying the pathophysiology of secondary hyperparathyroidism are well known, new evidence has shed light on unknown aspects of the deregulation of parathyroid function. Secondary hyperparathyroidism is an important feature of chronic kidney disease-mineral and bone disorder and plays an important role in the development of bone disease and vascular calcification. Thus, part of the management of chronic kidney disease relies on maintaining acceptable levels of mineral metabolism parameters in an attempt to slow down or prevent the development of secondary hyperparathyroidism. Here, we will also review the latest evidence regarding several aspects of the clinical and surgical management of secondary hyperparathyroidism.

Citing Articles

Beyond secondary hyperparathyroidism: Diagnosing primary parathyroid abnormalities in a patient with chronic kidney disease.

Strakosha A, Pasko N, Cadri V, Rista E, Aliu D, Arapi B Radiol Case Rep. 2024; 19(12):6385-6389.

PMID: 39387009 PMC: 11461942. DOI: 10.1016/j.radcr.2024.08.142.


COVID-19-Induced Refractory Symptomatic Hypocalcemia in a Patient With Parathyroid Gland Reimplantation.

Tse C, Yeung H Case Rep Endocrinol. 2024; 2024:6375828.

PMID: 39355148 PMC: 11444793. DOI: 10.1155/2024/6375828.


Changes in cardiac functions in patients treated with parathyroidectomy for secondary hyperparathyroidism.

Benli S, Yesil E, Tazeoglu D, Ozcan C, Ozcan I, Dag A Updates Surg. 2024; 76(4):1443-1452.

PMID: 38530609 PMC: 11341577. DOI: 10.1007/s13304-024-01812-8.


Pharmacokinetics, Pharmacodynamics, and Safety of Evocalcet (KHK7580), a Novel Calcimimetic Agent: An Open-Label, Single- and Multiple-Dose, Phase I Trial in Healthy Chinese Subjects.

He X, Narushima K, Kojima M, Nagai C, Li K Drug Des Devel Ther. 2024; 18:567-581.

PMID: 38436038 PMC: 10906727. DOI: 10.2147/DDDT.S437903.


Real-world usage of Chronic Kidney Disease - Mineral Bone Disorder (CKD-MBD) biomarkers in nephrology practices.

Fusaro M, Barbuto S, Gallieni M, Cossettini A, Re Sarto G, Cosmai L Clin Kidney J. 2024; 17(1):sfad290.

PMID: 38223338 PMC: 10784916. DOI: 10.1093/ckj/sfad290.


References
1.
Cunningham J, Block G, Chertow G, Cooper K, Evenepoel P, Iles J . Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients. Kidney Int Rep. 2019; 4(7):987-994. PMC: 6611952. DOI: 10.1016/j.ekir.2019.04.010. View

2.
Naveh-Many T, Rahamimov R, Livni N, Silver J . Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Invest. 1995; 96(4):1786-93. PMC: 185815. DOI: 10.1172/JCI118224. View

3.
Shilo V, Mor-Yosef Levi I, Abel R, Mihailovic A, Wasserman G, Naveh-Many T . and Regulate Parathyroid Hormone Levels in Secondary Hyperparathyroidism. J Am Soc Nephrol. 2017; 28(8):2353-2363. PMC: 5533223. DOI: 10.1681/ASN.2016050585. View

4.
Raggi P, Chertow G, Urena Torres P, Csiky B, Naso A, Nossuli K . The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant. 2010; 26(4):1327-39. DOI: 10.1093/ndt/gfq725. View

5.
Sadowski S, Pusztaszeri M, Brulhart-Meynet M, Petrenko V, De Vito C, Sobel J . Identification of Differential Transcriptional Patterns in Primary and Secondary Hyperparathyroidism. J Clin Endocrinol Metab. 2018; 103(6):2189-2198. DOI: 10.1210/jc.2017-02506. View